Japan Lifeline logo

Japan Lifeline

Asia, Tokyo, Japan, Tokyo

Description

Japan Lifeline is an independent medical device company that engages in two types of business, trading and manufacturing.

Investor Profile

Japan Lifeline has made 3 investments, with 0 in the past 12 months and 0% as lead.

Stage Focus

  • Series B (67%)
  • Series A (33%)

Country Focus

  • Japan (100%)

Industry Focus

  • Health Care
  • Medical
  • Biotechnology
  • Artificial Intelligence (Ai)
  • Nursing And Residential Care
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Japan Lifeline frequently co-invest with?

Daiwa Corporate Investment
Asia, Tokyo, Japan, Tokyo
Co-Investments: 1
Dai-ichi Life
Asia, Tokyo, Japan, Tokyo
Co-Investments: 2
Globis Capital Partners
Asia, Tokyo, Japan, Tokyo
Co-Investments: 1
F-Prime Capital
North America, Massachusetts, United States, Cambridge
Co-Investments: 2
Aflac Global Ventures
North America, Georgia, United States, Columbus
Co-Investments: 1
Japan Post Capital
Asia, Tokyo, Japan, Tokyo
Co-Investments: 1
Sony Innovation Fund
Asia, Tokyo, Japan, Tokyo
Co-Investments: 2
Eight Roads Ventures
Europe, England, United Kingdom, London
Co-Investments: 2
KSP
Asia, Kanagawa, Japan, Kawasaki
Co-Investments: 2
IG
Asia, Tokyo, Japan, Tokyo
Co-Investments: 1

What are some of recent deals done by Japan Lifeline?

Metcela

Kawasaki, Kanagawa, Japan

Metcela is a clinical-stage biotech startup providing patients with an alternative treatment option for heart disease.

BiotechnologyHealth CareMedical
Series BJan 4, 2021
Amount Raised: $12,700,000
AI Medical Service

Toshima, Tokyo, Japan

AI Medical Service is a Tokyo-based company developing AI software to help detect gastric cancer.

Artificial Intelligence (AI)Health CareMedicalNursing and Residential Care
Series BOct 4, 2019
Amount Raised: $43,010,681
Metcela

Kawasaki, Kanagawa, Japan

Metcela is a clinical-stage biotech startup providing patients with an alternative treatment option for heart disease.

BiotechnologyHealth CareMedical
Series AAug 30, 2018
Amount Raised: $4,684,199